Latest News and Press Releases
Want to stay updated on the latest news?
-
WHY: NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene,...
-
NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BeiGene,...
-
WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial...
-
Dublin, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Head & Neck Cancer Drugs Market (2022-2027) by Drug Class, Product, End User, Geography, Competitive Analysis and the Impact of Covid-19...
-
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...
-
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of...
-
Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends...
-
CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
-
BEIJING, China and CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
-
CAMBRIDGE, Mass. and BEIJING, China, July 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...